DK2658870T3 - Konjugerede anti-cd38-antistoffer - Google Patents
Konjugerede anti-cd38-antistoffer Download PDFInfo
- Publication number
- DK2658870T3 DK2658870T3 DK11810777.0T DK11810777T DK2658870T3 DK 2658870 T3 DK2658870 T3 DK 2658870T3 DK 11810777 T DK11810777 T DK 11810777T DK 2658870 T3 DK2658870 T3 DK 2658870T3
- Authority
- DK
- Denmark
- Prior art keywords
- ser
- val
- leu
- gly
- thr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (12)
1. Isoleret antistof, der specifikt binder human-CD38 (SEQ ID NO: 1) og cynomolgus-CD38 (SEQ ID NO: 2), som omfatter: a) en variabel region af tung kæde, der omfatter SEQ ID NO: 9; b) en variabel region af let kæde, der omfatter SEQ ID NO: 10; og c) en kovalent bundet lægemiddeldel.
2. Isoleret antistof ifølge krav 1, hvor den tunge kæde omfatter SEQ ID NO: 21, og den lette kæde omfatter SEQ ID NO: 22.
3. Isoleret antistof ifølge krav 1, der yderligere omfatter et Fc-domæne.
4. Isoleret antistof ifølge krav 3, hvor Fc-domænet er humant eller et variant-Fc-domæne.
5. Isoleret antistof ifølge et hvilket som helst af ovennævnte krav, hvor lægemiddeldelen er bundet til antistoffet ved anvendelse af en linker.
6. Isoleret antistof ifølge krav 5, hvor lægemiddeldelen er valgt fra gruppen, der består af en auristatin, et maytansinoid, en calicheamicin, en dolstatin og en trichothecen.
7. Værtscelle, der omfatter en isoleret nukleinsyre, der koder for den tunge kæde ifølge krav 1, og en isoleret nukleinsyre, der koder for den lette kæde ifølge krav 1.
8. Fremgangsmåde til fremstilling af antistoffet ifølge krav 1, som omfatter dyrkning af værtscellen ifølge krav 7 under betingelser, hvor antistoffet dannes.
9. Isoleret antistof ifølge krav 1 til anvendelse til behandling af cancer.
10. Isoleret antistof til anvendelse til behandling af cancer ifølge krav 9, hvor canceren er hæmatologisk cancer og valgt fra gruppen, der består af multipelt myelom, kronisk lymfoblastisk leukæmi, kronisk lymfocytisk leukæmi, plasmacelleleukæmi, akut myeloid leukæmi, kronisk myeloid leukæmi, B-cellelymfom og Burkitts lymfom.
11. Isoleret antistof til anvendelse til behandling af cancer ifølge krav 10, hvor den hæmotologiske cancer er multipelt myelom.
12. Isoleret antistof ifølge krav 1 til anvendelse som et medikament.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201061428699P | 2010-12-30 | 2010-12-30 | |
US201161470406P | 2011-03-31 | 2011-03-31 | |
US201161470382P | 2011-03-31 | 2011-03-31 | |
US201161485104P | 2011-05-11 | 2011-05-11 | |
PCT/US2011/068244 WO2012092616A1 (en) | 2010-12-30 | 2011-12-30 | Conjugated anti-cd38 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2658870T3 true DK2658870T3 (da) | 2018-08-06 |
Family
ID=45498158
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17189925.5T DK3284754T3 (da) | 2010-12-30 | 2011-12-30 | Anti-cd38-antistoffer |
DK11811633.4T DK2658871T3 (da) | 2010-12-30 | 2011-12-30 | Anti-cd38-antistoffer |
DK11810777.0T DK2658870T3 (da) | 2010-12-30 | 2011-12-30 | Konjugerede anti-cd38-antistoffer |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17189925.5T DK3284754T3 (da) | 2010-12-30 | 2011-12-30 | Anti-cd38-antistoffer |
DK11811633.4T DK2658871T3 (da) | 2010-12-30 | 2011-12-30 | Anti-cd38-antistoffer |
Country Status (38)
Country | Link |
---|---|
US (10) | US9102744B2 (da) |
EP (6) | EP2658871B1 (da) |
JP (10) | JP6148984B2 (da) |
KR (5) | KR102070326B1 (da) |
CN (3) | CN113480649A (da) |
AR (1) | AR084747A1 (da) |
AU (3) | AU2011351921B2 (da) |
BR (1) | BR112013017009B1 (da) |
CA (1) | CA2822061C (da) |
CO (1) | CO6761368A2 (da) |
CR (1) | CR20130313A (da) |
CY (3) | CY1122161T1 (da) |
DK (3) | DK3284754T3 (da) |
EA (2) | EA201791186A1 (da) |
EC (1) | ECSP13012794A (da) |
ES (3) | ES2690095T3 (da) |
GE (1) | GEP20166493B (da) |
HK (2) | HK1245284A1 (da) |
HR (3) | HRP20181176T1 (da) |
HU (3) | HUE052906T2 (da) |
IL (1) | IL226973A (da) |
JO (2) | JOP20210044A1 (da) |
LT (3) | LT2658870T (da) |
MA (1) | MA34763B1 (da) |
MX (2) | MX350903B (da) |
MY (1) | MY160499A (da) |
NZ (2) | NZ612272A (da) |
PE (1) | PE20140247A1 (da) |
PL (3) | PL2658871T3 (da) |
PT (3) | PT3284754T (da) |
RS (3) | RS57526B1 (da) |
SG (1) | SG191211A1 (da) |
SI (3) | SI2658871T1 (da) |
TR (1) | TR201808709T4 (da) |
TW (1) | TWI564304B (da) |
UY (1) | UY33850A (da) |
WO (2) | WO2012092612A1 (da) |
ZA (1) | ZA201304696B (da) |
Families Citing this family (184)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA06008700A (es) | 2004-02-06 | 2007-01-19 | Morphosys Ag | Anticuerpos anti-cd38 humanos y usos para los mismos. |
US9200061B2 (en) * | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
EP1945671A2 (en) | 2005-10-12 | 2008-07-23 | MorphoSys AG | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
RU2595839C2 (ru) | 2010-09-27 | 2016-08-27 | МорфоСис АГ | Антитело к cd38 и леналидомид или бортезомиб для лечения множественной миеломы и nhl |
JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
BR112014009925B1 (pt) | 2011-10-28 | 2022-09-20 | Teva Pharmaceuticals Australia Pty Ltd | Construtores de polipeptídeos e seus usos |
JP6224586B2 (ja) | 2012-07-10 | 2017-11-01 | 武田薬品工業株式会社 | 注射用製剤 |
RU2650618C2 (ru) | 2012-09-25 | 2018-04-16 | МорфоСис АГ | Комбинации и их применение |
US10342869B2 (en) | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
UA118255C2 (uk) * | 2012-12-07 | 2018-12-26 | Санофі | Композиція, яка містить антитіло до cd38 і леналідомід |
BR112015024926A2 (pt) * | 2013-04-16 | 2017-10-10 | Genentech Inc | composições, artigo de fabricação, métodos para tratar um paciente com câncer, para avaliar uma composição, para avaliar a atividade biológica, para produzir uma composição e para avaliar a fragmentação de uma composição e variante de pertuzumabe |
PL3677591T3 (pl) * | 2013-04-29 | 2023-06-26 | Teva Pharmaceuticals Australia Pty Ltd | Przeciwciała anty-cd38 i fuzje z interferonem alfa-2b o osłabionej aktywności |
US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
SG10201803288RA (en) * | 2013-10-31 | 2018-05-30 | Sanofi Sa | Specific anti-cd38 antibodies for treating human cancers |
US9493563B2 (en) | 2013-11-04 | 2016-11-15 | Glenmark Pharmaceuticals S.A. | Production of T cell retargeting hetero-dimeric immunoglobulins |
WO2015123687A1 (en) * | 2014-02-14 | 2015-08-20 | Centrose, Llc | Extracellular targeted drug conjugates |
US9732154B2 (en) * | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
US9603927B2 (en) * | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
MA40253A (fr) | 2014-07-15 | 2017-05-24 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
JP2017528433A (ja) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のmTOR阻害剤とCARの組み合わせ |
EP3191187B1 (en) * | 2014-09-09 | 2021-07-28 | Janssen Biotech, Inc. | Combination therapies with anti-cd38 antibodies |
CA2965414C (en) | 2014-10-29 | 2024-01-09 | Teva Pharmaceuticals Australia Pty Ltd | Interferon .alpha.2.beta. variants |
MA40894A (fr) | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
KR102597989B1 (ko) * | 2014-12-04 | 2023-11-02 | 얀센 바이오테크 인코포레이티드 | 급성 골수성 백혈병을 치료하기 위한 항-cd38 항체 |
US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
MA41555A (fr) * | 2015-02-17 | 2017-12-26 | Millennium Pharm Inc | Polythérapie pour le traitement du cancer |
WO2016164669A2 (en) | 2015-04-08 | 2016-10-13 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind cd38 |
WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
MX2017014810A (es) * | 2015-05-20 | 2018-05-11 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38. |
PT3303373T (pt) | 2015-05-30 | 2020-07-14 | Molecular Templates Inc | Estruturas de subunidade a de toxina shiga desimunizadas e moléculas de direcionamento celular compreendendo as mesmas |
IL256242B1 (en) * | 2015-06-22 | 2024-05-01 | Janssen Biotech Inc | Combination therapies for HEME malignancies with anti-CD38 antibodies and sorbibin inhibitors |
US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
US20160376373A1 (en) | 2015-06-24 | 2016-12-29 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
UA124616C2 (uk) | 2015-07-06 | 2021-10-20 | Юсб Біофарма Срл | Зв'язуюче тау-білок антитіло |
MA42895A (fr) | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
EP3331913A1 (en) | 2015-08-07 | 2018-06-13 | Novartis AG | Treatment of cancer using chimeric cd3 receptor proteins |
EP3355937A4 (en) | 2015-09-28 | 2019-04-17 | Regents of the University of Minnesota | CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS AS THERAPEUTIC INTERVENTIONS AT AUTO AND ALLO IMMUNITY |
EP3819310A1 (en) | 2015-10-25 | 2021-05-12 | Sanofi | Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection |
ES2912729T3 (es) | 2015-11-03 | 2022-05-27 | Janssen Biotech Inc | Formulaciones subcutáneas de anticuerpos anti-CD38 y sus usos |
US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
JP7118887B2 (ja) | 2015-11-23 | 2022-08-16 | ノバルティス アーゲー | 最適化されたレンチウイルス移入ベクターおよびその使用 |
ES2944597T3 (es) | 2015-12-30 | 2023-06-22 | Novartis Ag | Terapias con células efectoras inmunitarias de eficacia mejorada |
CN105546709B (zh) * | 2016-02-04 | 2019-01-04 | 山东格瑞德集团有限公司 | 孔板送风布风*** |
CA3016098A1 (en) * | 2016-03-04 | 2017-09-08 | Morphosys Ag | Clinical assessment of m-protein response in multiple myeloma |
EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
MY192090A (en) | 2016-04-13 | 2022-07-26 | Sanofi Sa | Trispecific and/or trivalent binding proteins |
WO2017191214A1 (en) * | 2016-05-03 | 2017-11-09 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Cd31shed as a molecular target for imaging of inflammation |
WO2018002181A1 (en) * | 2016-06-28 | 2018-01-04 | Umc Utrecht Holding B.V. | TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38 |
EP3484923A1 (en) | 2016-07-15 | 2019-05-22 | Takeda Pharmaceutical Company Limited | Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies |
WO2018014067A1 (en) | 2016-07-19 | 2018-01-25 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd47 combination therapy |
JP2019521171A (ja) | 2016-07-20 | 2019-07-25 | ヒブリジェニクス・エスアー | 抗cd38薬剤とのイネカルシトールの組み合わせ、及び癌を治療するためのその使用 |
CN110167964B (zh) | 2016-11-02 | 2023-12-01 | 百时美施贵宝公司 | 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物 |
US20210333279A1 (en) * | 2016-11-04 | 2021-10-28 | Aarhus Universitet | Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor |
WO2018111340A1 (en) | 2016-12-16 | 2018-06-21 | Novartis Ag | Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells |
WO2018140725A1 (en) | 2017-01-26 | 2018-08-02 | Novartis Ag | Cd28 compositions and methods for chimeric antigen receptor therapy |
WO2018144535A1 (en) | 2017-01-31 | 2018-08-09 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
US20200048359A1 (en) | 2017-02-28 | 2020-02-13 | Novartis Ag | Shp inhibitor compositions and uses for chimeric antigen receptor therapy |
EP3597217A4 (en) * | 2017-03-01 | 2021-01-13 | Institute for Rheumatic Diseases Co., Ltd. | PROPHYLACTIC AND / OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE AND VACCINE |
EA201892312A1 (ru) | 2017-03-17 | 2019-04-30 | Санофи | Триспецифические и/или тривалентные связывающие белки |
JP7050333B2 (ja) | 2017-03-24 | 2022-04-08 | 全薬工業株式会社 | 抗IgM/B細胞表面抗原二重特異性抗体 |
WO2018183376A1 (en) * | 2017-03-28 | 2018-10-04 | Rigel Pharmaceuticals, Inc. | Acvr2a-specific antibody and method of use thereof |
WO2018189382A1 (en) | 2017-04-14 | 2018-10-18 | Solstice Biologics, Ltd. | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use |
CN111051344B (zh) * | 2017-06-08 | 2023-10-27 | 黑带医疗有限公司 | Cd38调节抗体 |
CA3066553A1 (en) * | 2017-06-08 | 2018-12-13 | Black Belt Therapeutics Limited | Cd38 modulating antibody |
WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
CA3067311A1 (en) * | 2017-06-20 | 2018-12-27 | Sorrento Therapeutics, Inc. | Cd38 antibody drug conjugate |
MX2019015841A (es) | 2017-06-20 | 2020-08-03 | Inst Curie | Celulas inmunes defectuosas para suv39h1. |
EP3434692A1 (en) * | 2017-07-24 | 2019-01-30 | Encefa | Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases |
WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
US11542338B2 (en) | 2017-08-16 | 2023-01-03 | Black Belt Therapeutics Limited | CD38 modulating antibody |
SG11202000321PA (en) * | 2017-08-16 | 2020-02-27 | Black Belt Therapeutics Ltd | Cd38 modulating antibody |
EP3668543A1 (en) | 2017-08-16 | 2020-06-24 | Black Belt Therapeutics Limited | Cd38 antibody |
EP3681908A1 (en) | 2017-09-13 | 2020-07-22 | Teneobio, Inc. | Heavy chain antibodies binding to ectoenzymes |
EP4249068A3 (en) | 2017-10-10 | 2023-11-22 | Sanofi | Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies |
SG11202003177RA (en) | 2017-10-25 | 2020-05-28 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
WO2019081983A1 (en) | 2017-10-25 | 2019-05-02 | Novartis Ag | CD32B TARGETING ANTIBODIES AND METHODS OF USE |
WO2019089798A1 (en) | 2017-10-31 | 2019-05-09 | Novartis Ag | Anti-car compositions and methods |
AU2018359527A1 (en) | 2017-10-31 | 2020-05-07 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
US11564946B2 (en) | 2017-11-01 | 2023-01-31 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
US20210254000A1 (en) | 2017-11-01 | 2021-08-19 | Juno Therapeutics, Inc. | Process for producing a t cell composition |
WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
CA3082010A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for b-cell maturation antigen (bcma) |
BR112020008323A2 (pt) | 2017-11-01 | 2020-11-03 | Juno Therapeutics Inc | anticorpos e receptores de antígenos quiméricos específicos para antígeno de maturação de células b |
CN111542596A (zh) | 2017-11-01 | 2020-08-14 | 朱诺治疗学股份有限公司 | 产生工程化细胞的治疗性组合物的方法 |
CA3080109A1 (en) | 2017-11-03 | 2019-05-09 | Sorrento Therapeutics, Inc. | Cd38-directed chimeric antigen receptor constructs |
CA3082442A1 (en) * | 2017-11-30 | 2019-06-06 | Genentech, Inc. | Anti-pd-l1 antibodies and methods of using the same for detection of pd-l1 |
WO2019111249A1 (en) * | 2017-12-05 | 2019-06-13 | The Medical Research Infrastructure And Health Services Fund Of The Tel Aviv Medical Center | T-cells comprising anti-cd38 and anti-cd138 chimeric antigen receptors and uses thereof |
AU2018379091A1 (en) | 2017-12-08 | 2020-06-25 | Juno Therapeutics, Inc. | Serum-free media formulation for culturing cells and methods of use thereof |
BR112020011215A2 (pt) | 2017-12-08 | 2020-11-17 | Juno Therapeutics Inc | processo para a produção de uma composição de células t modificadas |
CN112203680A (zh) | 2017-12-08 | 2021-01-08 | 朱诺治疗学股份有限公司 | 用于细胞疗法的表型标记和相关方法 |
AU2019208102A1 (en) * | 2018-01-12 | 2020-07-02 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-CD38 antibodies |
CN110144008B (zh) * | 2018-02-12 | 2021-03-19 | 杭州尚健生物技术有限公司 | Cd38蛋白抗体及其应用 |
WO2019186273A1 (en) * | 2018-03-28 | 2019-10-03 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-cd38 antibodies |
CN108318689A (zh) * | 2018-04-09 | 2018-07-24 | 北京大学深圳研究生院 | 一种多发性骨髓瘤的诊断方法 |
EP3784351A1 (en) | 2018-04-27 | 2021-03-03 | Novartis AG | Car t cell therapies with enhanced efficacy |
EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
US20210213063A1 (en) | 2018-05-25 | 2021-07-15 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
US20210123075A1 (en) | 2018-06-08 | 2021-04-29 | Novartis Ag | Compositions and methods for immunooncology |
CN108752475B (zh) * | 2018-06-14 | 2021-07-30 | 北京智仁美博生物科技有限公司 | 抗人cd38抗体及其用途 |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
PE20211858A1 (es) | 2018-07-13 | 2021-09-21 | Genmab As | Variantes de anticuerpos anti-cd38 y sus usos |
JP2021526845A (ja) | 2018-07-13 | 2021-10-11 | ゲンマブ エー/エス | Cd38抗体を使用したトロゴサイトーシスを介した治療 |
MX2021001519A (es) | 2018-08-09 | 2021-05-27 | Juno Therapeutics Inc | Metodos para valorar acidos nucleicos integrados. |
KR20210057752A (ko) * | 2018-09-11 | 2021-05-21 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 항-cd38 항체, 이의 항원 결합 단편, 및 제약 용도 |
CN109053892B (zh) * | 2018-09-19 | 2021-03-26 | 苏州思坦维生物技术股份有限公司 | 特异结合人及猴cd38抗原的单克隆抗体及其制备方法与应用 |
JP7462621B2 (ja) | 2018-10-09 | 2024-04-05 | サノフイ | 三重特異性抗cd38、抗cd28、および抗cd3結合タンパク質ならびにウイルス感染を処置するための使用方法 |
AU2019367218A1 (en) | 2018-10-26 | 2021-06-03 | TeneoFour, Inc. | Heavy chain antibodies binding to CD38 |
AU2019374103A1 (en) | 2018-11-01 | 2021-05-20 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D) |
CN113646335A (zh) | 2018-11-01 | 2021-11-12 | 朱诺治疗学股份有限公司 | 使用对b细胞成熟抗原具有特异性的嵌合抗原受体的治疗的方法 |
BR112021011399A2 (pt) | 2018-12-14 | 2021-09-14 | Morphosys Ag | Formulação farmacêutica liofilizada, método para preparar uma formulação líquida de um anticorpo anti-cd38, formulação farmacêutica reconstituída e uso de uma formulação farmacêutica |
KR20210106437A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
CN113454108A (zh) | 2019-01-23 | 2021-09-28 | 米伦纽姆医药公司 | 包含去免疫化志贺菌毒素a亚基效应子的cd38结合蛋白 |
EP3914358A1 (en) | 2019-01-23 | 2021-12-01 | Millennium Pharmaceuticals, Inc. | Anti-cd38 antibodies |
BR112021014574A2 (pt) * | 2019-01-23 | 2021-10-05 | Encefa | Competidores cd31 e usos dos mesmos |
EP3924055B1 (en) | 2019-02-15 | 2024-04-03 | Novartis AG | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
US20220144807A1 (en) | 2019-02-15 | 2022-05-12 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
EP3938394A1 (en) | 2019-03-15 | 2022-01-19 | MorphoSys AG | Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease |
US20200308284A1 (en) * | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Lenalidomide and Dexamethasone |
US20200330593A1 (en) * | 2019-03-28 | 2020-10-22 | Janssen Biotech, Inc. | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib, Mephalan and Prednisone |
WO2020194242A1 (en) * | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with pomalidomide and dexamethasone |
US20200316197A1 (en) * | 2019-03-28 | 2020-10-08 | Janssen Biotech, Inc. | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone |
CA3134612A1 (en) * | 2019-03-29 | 2020-10-08 | Sorrento Therapeutics, Inc. | Engineered variant antibodies that bind cd38 |
WO2020210392A1 (en) * | 2019-04-09 | 2020-10-15 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
WO2020223571A1 (en) | 2019-05-01 | 2020-11-05 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods |
AU2020265741A1 (en) | 2019-05-01 | 2021-11-25 | Editas Medicine, Inc. | Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods |
EP3980064A1 (en) | 2019-06-10 | 2022-04-13 | Takeda Pharmaceutical Company Limited | Combination therapies using cd-38 antibodies |
CA3144871A1 (en) | 2019-06-27 | 2020-12-30 | Crispr Therapeutics Ag | Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer |
WO2021003074A1 (en) * | 2019-07-03 | 2021-01-07 | Crystal Bioscience Inc. | Anti-cd38 antibody and methods of use thereof |
KR20220042161A (ko) | 2019-07-23 | 2022-04-04 | 엥스띠뛰 퀴리 | Suv39h1에 결함이 있는 면역 세포 |
CN112538114A (zh) * | 2019-09-20 | 2021-03-23 | 上海普铭生物科技有限公司 | 抗人cd38抗体及其应用 |
EP4054714A4 (en) * | 2019-11-07 | 2023-12-06 | Ohio State Innovation Foundation | METHODS AND COMPOSITIONS FOR SELECTIVE INTRACELLULAR DELIVERY OF CD38 INHIBITORS |
CN112876563B (zh) * | 2019-11-29 | 2022-08-16 | 康诺亚生物医药科技(成都)有限公司 | 药物组合物及其制备方法和应用 |
MX2022007613A (es) | 2019-12-18 | 2022-07-19 | Teneofour Inc | Union de anticuerpos de cadena pesada a cd38. |
WO2021123996A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
IL294453A (en) | 2020-01-16 | 2022-09-01 | Genmab As | Formulations of cd38 antibodies and uses thereof |
CN115427458A (zh) | 2020-02-28 | 2022-12-02 | 塔拉克治疗公司 | 转谷氨酰胺酶介导的缀合 |
BR112022018987A2 (pt) | 2020-03-26 | 2022-11-01 | Seagen Inc | Métodos de tratamento de mieloma múltiplo |
KR20230009386A (ko) | 2020-04-10 | 2023-01-17 | 주노 쎄러퓨티크스 인코퍼레이티드 | B-세포 성숙 항원을 표적화하는 키메라 항원 수용체로 조작된 세포 요법 관련 방법 및 용도 |
WO2021226584A1 (en) * | 2020-05-08 | 2021-11-11 | University Of Southern California | Site-specific antibody-drug conjugates by adp-ribosyl cyclases |
EP4150640A1 (en) | 2020-05-13 | 2023-03-22 | Juno Therapeutics, Inc. | Methods of identifying features associated with clinical response and uses thereof |
AU2021288224A1 (en) | 2020-06-11 | 2023-01-05 | Novartis Ag | ZBTB32 inhibitors and uses thereof |
CN115916199A (zh) | 2020-06-23 | 2023-04-04 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案 |
KR20230042283A (ko) | 2020-06-26 | 2023-03-28 | 주노 테라퓨틱스 게엠베하 | 재조합 수용체를 조건부로 발현하는 조작된 t 세포, 관련된 폴리뉴클레오티드 및 방법 |
US20220023344A1 (en) | 2020-06-26 | 2022-01-27 | Crispr Therapeutics Ag | Allogeneic cell therapy of acute lymphoblastic leukemia using genetically engineered t cells targeting cd19 |
US20230303974A1 (en) | 2020-07-30 | 2023-09-28 | Institut Curie | Immune Cells Defective for SOCS1 |
US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
WO2022098787A1 (en) | 2020-11-04 | 2022-05-12 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods |
US20240018248A1 (en) | 2020-12-02 | 2024-01-18 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
WO2022137186A1 (en) | 2020-12-23 | 2022-06-30 | Crispr Therapeutics Ag | Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor |
JP2024509853A (ja) | 2021-03-03 | 2024-03-05 | ジュノー セラピューティクス インコーポレイテッド | T細胞療法およびdgk阻害剤の組合せ |
JPWO2022196719A1 (da) | 2021-03-17 | 2022-09-22 | ||
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
TW202309294A (zh) | 2021-04-27 | 2023-03-01 | 瑞士商諾華公司 | 病毒載體生產系統 |
WO2022234009A2 (en) | 2021-05-06 | 2022-11-10 | Juno Therapeutics Gmbh | Methods for stimulating and transducing t cells |
WO2022238386A1 (en) | 2021-05-10 | 2022-11-17 | Institut Curie | Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases |
AR125851A1 (es) | 2021-05-12 | 2023-08-16 | Crispr Therapeutics Ag | Células inmunes modificadas genéticamente que se focalizan en cd70 para su uso en el tratamiento de neoplasias malignas hematopoyéticas |
TW202309077A (zh) | 2021-05-12 | 2023-03-01 | 瑞士商Crispr治療公司 | 用於治療實性瘤的靶向cd70的基因工程化免疫細胞 |
WO2022242892A1 (en) * | 2021-05-17 | 2022-11-24 | Université de Liège | Anti-cd38 single-domain antibodies in disease monitoring and treatment |
EP4346912A1 (en) | 2021-05-25 | 2024-04-10 | Institut Curie | Myeloid cells overexpressing bcl2 |
WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
IL310372A (en) | 2021-07-28 | 2024-03-01 | Genentech Inc | IL15/IL15R alpha heterodimeric FC-fused proteins for the treatment of blood cancer |
WO2023017392A1 (en) | 2021-08-13 | 2023-02-16 | 3M Innovative Properties Company | Antistatic fabric article |
CN113896802A (zh) * | 2021-10-09 | 2022-01-07 | 宜明昂科生物医药技术(上海)有限公司 | 靶向cd47和cd38的重组融合蛋白及其制备和用途 |
WO2023126458A1 (en) | 2021-12-28 | 2023-07-06 | Mnemo Therapeutics | Immune cells with inactivated suv39h1 and modified tcr |
WO2023147515A1 (en) | 2022-01-28 | 2023-08-03 | Juno Therapeutics, Inc. | Methods of manufacturing cellular compositions |
WO2023159182A1 (en) | 2022-02-18 | 2023-08-24 | Rakuten Medical, Inc. | Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use |
WO2023187024A1 (en) | 2022-03-31 | 2023-10-05 | Institut Curie | Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression |
WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
WO2023213969A1 (en) | 2022-05-05 | 2023-11-09 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
WO2023230548A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Method for predicting response to a t cell therapy |
WO2023230581A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Methods of manufacturing t cell therapies |
WO2024054944A1 (en) | 2022-09-08 | 2024-03-14 | Juno Therapeutics, Inc. | Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing |
WO2024054775A1 (en) * | 2022-09-09 | 2024-03-14 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-cd38 antibodies for treating patients with moderate to severe systemic lupus erythematosus |
WO2024079010A1 (en) | 2022-10-10 | 2024-04-18 | F. Hoffmann-La Roche Ag | Combination therapy of a gprc5d tcb and cd38 antibodies |
WO2024089639A1 (en) | 2022-10-26 | 2024-05-02 | Novartis Ag | Lentiviral formulations |
WO2024094660A1 (en) | 2022-10-31 | 2024-05-10 | Genmab A/S | Cd38 antibodies and uses thereof |
WO2024100604A1 (en) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Methods for manufacturing engineered immune cells |
WO2024124132A1 (en) | 2022-12-09 | 2024-06-13 | Juno Therapeutics, Inc. | Machine learning methods for predicting cell phenotype using holographic imaging |
Family Cites Families (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
US4169888A (en) | 1977-10-17 | 1979-10-02 | The Upjohn Company | Composition of matter and process |
US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4970198A (en) | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
DE3783588T2 (de) | 1986-04-17 | 1993-06-09 | Kyowa Hakko Kogyo Kk | Neue verbindungen dc-88a und dc-89a1 und deren herstellungsverfahren. |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
IL89220A (en) | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Immunoconjugates of anthracycline, their production and pharmaceutical preparations containing them |
US5084468A (en) | 1988-08-11 | 1992-01-28 | Kyowa Hakko Kogyo Co., Ltd. | Dc-88a derivatives |
JP2598116B2 (ja) | 1988-12-28 | 1997-04-09 | 協和醗酵工業株式会社 | 新規物質dc113 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5187186A (en) | 1989-07-03 | 1993-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Pyrroloindole derivatives |
JP2510335B2 (ja) | 1989-07-03 | 1996-06-26 | 協和醗酵工業株式会社 | Dc―88a誘導体 |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
IE911537A1 (en) | 1990-05-07 | 1991-11-20 | Scripps Clinic Res | Intermediates in the formation of the calicheamicin and¹esperamicin oligosaccharides |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
CA2076465C (en) | 1992-03-25 | 2002-11-26 | Ravi V. J. Chari | Cell binding agent conjugates of analogues and derivatives of cc-1065 |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5837242A (en) | 1992-12-04 | 1998-11-17 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
WO1994017184A1 (en) * | 1993-01-29 | 1994-08-04 | Schering Corporation | Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
ES2233928T3 (es) | 1993-10-01 | 2005-06-16 | Teikoku Hormone Mfg. Co., Ltd. | Derivados de dolastatina. |
WO1995029179A1 (fr) | 1994-04-22 | 1995-11-02 | Kyowa Hakko Kogyo Co., Ltd. | Derive de dc-89 |
JPH07309761A (ja) | 1994-05-20 | 1995-11-28 | Kyowa Hakko Kogyo Co Ltd | デュオカルマイシン誘導体の安定化法 |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5550246A (en) | 1994-09-07 | 1996-08-27 | The Scripps Research Institute | Calicheamicin mimics |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
PT871490E (pt) | 1995-12-22 | 2003-07-31 | Bristol Myers Squibb Co | Ligantes de hidrazona ramificada |
EP1325932B9 (en) | 1997-04-07 | 2006-07-19 | Genentech, Inc. | Anti-vegf antibodies |
PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
US7112661B1 (en) | 1998-10-30 | 2006-09-26 | The Research Foundation Of State University Of New York | Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha |
US7425541B2 (en) | 1998-12-11 | 2008-09-16 | Medarex, Inc. | Enzyme-cleavable prodrug compounds |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
US6939545B2 (en) | 1999-04-28 | 2005-09-06 | Genetics Institute, Llc | Composition and method for treating inflammatory disorders |
EP2289549A3 (en) | 1999-10-01 | 2011-06-15 | Immunogen, Inc. | Immunoconjugates for treating cancer |
US7303749B1 (en) | 1999-10-01 | 2007-12-04 | Immunogen Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
JP4668498B2 (ja) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | ポリペプチドの製造方法 |
US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
CN102311986B (zh) | 2000-10-06 | 2015-08-19 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
EP1333032A4 (en) | 2000-10-06 | 2005-03-16 | Kyowa Hakko Kogyo Kk | METHOD FOR PURIFYING ANTIBODIES |
IT1320715B1 (it) | 2000-10-19 | 2003-12-10 | Cselt Centro Studi Lab Telecom | Modulo generatore di circuiti per la decodifica di codiciconvoluzionali, metodo per la generazione di tale tipo di circuito e |
ES2649037T3 (es) | 2000-12-12 | 2018-01-09 | Medimmune, Llc | Moléculas con semividas prolongadas, composiciones y usos de las mismas |
EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
EP2009027B1 (en) * | 2001-04-27 | 2014-05-21 | Kyowa Hakko Kirin Co., Ltd. | Anti-CD40 monoclonal antibody |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
MXPA03011094A (es) | 2001-05-31 | 2004-12-06 | Medarex Inc | Citotoxinas, profarmacos, ligadores, y estabilizadores utiles para ello. |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
EP1539233B1 (en) | 2001-07-12 | 2011-04-27 | FOOTE, Jefferson | Super humanized antibodies |
US7497862B2 (en) | 2001-08-03 | 2009-03-03 | Tyco Healthcare Group Lp | Tissue marking apparatus and method |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
WO2004010957A2 (en) | 2002-07-31 | 2004-02-05 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
DE10246870B3 (de) | 2002-10-08 | 2004-04-29 | Renk Aktiengesellschaft | Elektro-Hydrodynamische Überlagerungslenkung |
CN100526460C (zh) * | 2002-11-08 | 2009-08-12 | 麒麟医药株式会社 | 朊病毒蛋白活性降低的转基因有蹄类动物及其用途 |
AU2003282624A1 (en) | 2002-11-14 | 2004-06-03 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
US7610156B2 (en) | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
LT3524611T (lt) | 2003-05-20 | 2021-04-12 | Immunogen, Inc. | Patobulinti citotoksiniai agentai, apimantys naujus maitansinoidus |
BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
WO2005084390A2 (en) | 2004-03-02 | 2005-09-15 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
US7691962B2 (en) | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
US7517903B2 (en) | 2004-05-19 | 2009-04-14 | Medarex, Inc. | Cytotoxic compounds and conjugates |
CA2580141C (en) | 2004-09-23 | 2013-12-10 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
ES2716874T3 (es) * | 2005-03-23 | 2019-06-17 | Genmab As | Anticuerpos contra cd38 para el tratamiento del mieloma múltiple |
US7714016B2 (en) | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
AU2006236225C1 (en) | 2005-04-19 | 2013-05-02 | Seagen Inc. | Humanized anti-CD70 binding agents and uses thereof |
EP2799451A1 (en) * | 2005-05-24 | 2014-11-05 | MorphoSys AG | Generation and profiling of fully human HuCAL GOLD®-derived therapeutic antibodies specific for human CD38 |
HUE057936T2 (hu) | 2005-07-18 | 2022-06-28 | Seagen Inc | Béta-glükuronid-linker-hatóanyag konjugátumok |
US8158590B2 (en) | 2005-08-05 | 2012-04-17 | Syntarga B.V. | Triazole-containing releasable linkers, conjugates thereof, and methods of preparation |
WO2007041635A2 (en) | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
EP1945671A2 (en) * | 2005-10-12 | 2008-07-23 | MorphoSys AG | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
PL1940789T3 (pl) | 2005-10-26 | 2012-04-30 | Squibb & Sons Llc | Metody i związki do otrzymywania analogów cc-1065 |
CA2627190A1 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
CN101415679A (zh) | 2006-02-02 | 2009-04-22 | 辛塔佳有限公司 | 水溶性cc-1065类似物及其缀合物 |
EP2975057A1 (en) | 2006-07-10 | 2016-01-20 | Fujita Health University | Novel anti-cd73 antibody |
DK2081595T3 (da) | 2006-09-26 | 2019-07-15 | Genmab As | Anti-cd38 plus corticosteroid plus et ikke-corticosteroid kemoterapeutikum til behandling af tumorer |
EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
WO2009017394A1 (en) | 2007-08-01 | 2009-02-05 | Syntarga B.V. | Substituted cc-1065 analogs and their conjugates |
US20090076249A1 (en) | 2007-09-19 | 2009-03-19 | Michel De Weers | Antibodies against CD38 for treatment of multiple myeloma |
JP5737944B2 (ja) * | 2007-12-17 | 2015-06-17 | ファイザー・リミテッドPfizer Limited | 間質性膀胱炎の治療 |
WO2010021874A2 (en) * | 2008-08-20 | 2010-02-25 | Centocor Ortho Biotech Inc. | Engineered anti-il-13 antibodies, compositions, methods and uses |
CN102317283A (zh) | 2008-11-03 | 2012-01-11 | 辛塔佳股份有限公司 | 新型cc-1065类似物及其缀合物 |
EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
EP2191843A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
EP2191841A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
EP2191842A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
JP5725508B2 (ja) | 2009-03-25 | 2015-05-27 | 国立大学法人東北大学 | Lh型二重特異性抗体 |
US10817851B2 (en) | 2009-12-23 | 2020-10-27 | Aristocrat Technologies Australia Pty Limited | System and method for cashless gaming |
UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
US11392902B2 (en) | 2017-06-06 | 2022-07-19 | United Parcel Service Of America, Inc. | Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery |
WO2020014526A2 (en) * | 2018-07-11 | 2020-01-16 | Anthony Manning | Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38 |
-
2010
- 2010-12-30 JO JOP/2021/0044A patent/JOP20210044A1/ar unknown
-
2011
- 2011-12-29 TW TW100149611A patent/TWI564304B/zh active
- 2011-12-29 JO JOP/2011/0402A patent/JOP20110402B1/ar active
- 2011-12-29 AR ARP110105024A patent/AR084747A1/es active IP Right Grant
- 2011-12-30 PT PT171899255T patent/PT3284754T/pt unknown
- 2011-12-30 LT LTEP11810777.0T patent/LT2658870T/lt unknown
- 2011-12-30 CN CN202110630414.2A patent/CN113480649A/zh active Pending
- 2011-12-30 KR KR1020197002704A patent/KR102070326B1/ko active IP Right Grant
- 2011-12-30 MY MYPI2013002489A patent/MY160499A/en unknown
- 2011-12-30 UY UY0001033850A patent/UY33850A/es not_active Application Discontinuation
- 2011-12-30 KR KR1020207001665A patent/KR102294213B1/ko active IP Right Grant
- 2011-12-30 RS RS20180859A patent/RS57526B1/sr unknown
- 2011-12-30 SG SG2013046651A patent/SG191211A1/en unknown
- 2011-12-30 LT LTEP11811633.4T patent/LT2658871T/lt unknown
- 2011-12-30 KR KR1020227034240A patent/KR102602640B1/ko active IP Right Grant
- 2011-12-30 ES ES11811633.4T patent/ES2690095T3/es active Active
- 2011-12-30 CN CN201710699217.XA patent/CN107365385A/zh active Pending
- 2011-12-30 HU HUE17189925A patent/HUE052906T2/hu unknown
- 2011-12-30 DK DK17189925.5T patent/DK3284754T3/da active
- 2011-12-30 PL PL11811633T patent/PL2658871T3/pl unknown
- 2011-12-30 PL PL17189925T patent/PL3284754T3/pl unknown
- 2011-12-30 HU HUE11811633A patent/HUE038727T2/hu unknown
- 2011-12-30 ES ES17189925T patent/ES2841299T3/es active Active
- 2011-12-30 DK DK11811633.4T patent/DK2658871T3/da active
- 2011-12-30 SI SI201131541T patent/SI2658871T1/sl unknown
- 2011-12-30 EA EA201791186A patent/EA201791186A1/ru unknown
- 2011-12-30 AU AU2011351921A patent/AU2011351921B2/en active Active
- 2011-12-30 RS RS20201556A patent/RS61280B1/sr unknown
- 2011-12-30 NZ NZ61227211A patent/NZ612272A/en unknown
- 2011-12-30 LT LTEP17189925.5T patent/LT3284754T/lt unknown
- 2011-12-30 EP EP11811633.4A patent/EP2658871B1/en active Active
- 2011-12-30 KR KR1020137017570A patent/KR101945002B1/ko active IP Right Grant
- 2011-12-30 EP EP20198444.0A patent/EP3789404A1/en active Pending
- 2011-12-30 BR BR112013017009-3A patent/BR112013017009B1/pt active IP Right Grant
- 2011-12-30 RS RS20180902A patent/RS57494B1/sr unknown
- 2011-12-30 PE PE2013001487A patent/PE20140247A1/es active IP Right Grant
- 2011-12-30 EP EP20189000.1A patent/EP3798231A1/en not_active Withdrawn
- 2011-12-30 EP EP17189927.1A patent/EP3284755B1/en active Active
- 2011-12-30 WO PCT/US2011/068235 patent/WO2012092612A1/en active Application Filing
- 2011-12-30 PT PT118116334T patent/PT2658871T/pt unknown
- 2011-12-30 US US13/977,207 patent/US9102744B2/en active Active
- 2011-12-30 WO PCT/US2011/068244 patent/WO2012092616A1/en active Application Filing
- 2011-12-30 US US13/341,860 patent/US8362211B2/en active Active
- 2011-12-30 KR KR1020217026369A patent/KR102451597B1/ko active IP Right Grant
- 2011-12-30 PL PL11810777T patent/PL2658870T3/pl unknown
- 2011-12-30 GE GEAP201113177A patent/GEP20166493B/en unknown
- 2011-12-30 HU HUE11810777A patent/HUE038535T2/hu unknown
- 2011-12-30 MX MX2013007455A patent/MX350903B/es active IP Right Grant
- 2011-12-30 JP JP2013547713A patent/JP6148984B2/ja active Active
- 2011-12-30 DK DK11810777.0T patent/DK2658870T3/da active
- 2011-12-30 CA CA2822061A patent/CA2822061C/en active Active
- 2011-12-30 EA EA201390993A patent/EA029303B1/ru unknown
- 2011-12-30 CN CN201180063232.6A patent/CN103282383B/zh active Active
- 2011-12-30 ES ES11810777.0T patent/ES2674175T3/es active Active
- 2011-12-30 EP EP17189925.5A patent/EP3284754B1/en active Active
- 2011-12-30 SI SI201131534T patent/SI2658870T1/sl unknown
- 2011-12-30 PT PT118107770T patent/PT2658870T/pt unknown
- 2011-12-30 JP JP2013547710A patent/JP5843884B2/ja active Active
- 2011-12-30 EP EP11810777.0A patent/EP2658870B1/en active Active
- 2011-12-30 SI SI201131939T patent/SI3284754T1/sl unknown
- 2011-12-30 NZ NZ705848A patent/NZ705848A/en unknown
-
2012
- 2012-12-19 US US13/720,837 patent/US8926969B2/en active Active
- 2012-12-30 TR TR2018/08709T patent/TR201808709T4/tr unknown
-
2013
- 2013-06-16 IL IL226973A patent/IL226973A/en active IP Right Grant
- 2013-06-21 CR CR20130313A patent/CR20130313A/es unknown
- 2013-06-24 ZA ZA2013/04696A patent/ZA201304696B/en unknown
- 2013-06-25 MX MX2020012426A patent/MX2020012426A/es unknown
- 2013-06-27 MA MA36052A patent/MA34763B1/fr unknown
- 2013-07-18 CO CO13170417A patent/CO6761368A2/es active IP Right Grant
- 2013-07-29 EC ECSP13012794 patent/ECSP13012794A/es unknown
-
2014
- 2014-11-21 US US14/550,796 patent/US9790285B2/en active Active
-
2015
- 2015-06-29 US US14/754,592 patent/US9676869B2/en active Active
- 2015-09-02 JP JP2015172783A patent/JP6425635B2/ja active Active
- 2015-12-18 JP JP2015247967A patent/JP6425644B2/ja active Active
-
2017
- 2017-05-17 US US15/598,241 patent/US10336833B2/en active Active
- 2017-07-04 AU AU2017204571A patent/AU2017204571B2/en active Active
- 2017-07-24 JP JP2017143106A patent/JP6621447B2/ja active Active
- 2017-07-24 JP JP2017143107A patent/JP6563446B2/ja active Active
- 2017-09-13 US US15/703,833 patent/US10494444B2/en active Active
-
2018
- 2018-03-28 HK HK18104295.4A patent/HK1245284A1/zh unknown
- 2018-07-23 HR HRP20181176TT patent/HRP20181176T1/hr unknown
- 2018-07-24 CY CY20181100773T patent/CY1122161T1/el unknown
- 2018-08-01 HR HRP20181245TT patent/HRP20181245T1/hr unknown
- 2018-08-02 CY CY20181100806T patent/CY1122165T1/el unknown
- 2018-08-08 HK HK18110205.0A patent/HK1250735A1/zh unknown
-
2019
- 2019-05-14 US US16/412,297 patent/US20200031951A1/en not_active Abandoned
- 2019-07-24 JP JP2019136165A patent/JP6766233B2/ja active Active
- 2019-09-25 JP JP2019174782A patent/JP6840813B2/ja active Active
- 2019-10-17 US US16/656,401 patent/US11434304B2/en active Active
- 2019-11-13 AU AU2019264573A patent/AU2019264573B2/en active Active
-
2020
- 2020-09-16 JP JP2020155609A patent/JP7096301B2/ja active Active
- 2020-12-14 HR HRP20201996TT patent/HRP20201996T1/hr unknown
- 2020-12-21 CY CY20201101205T patent/CY1123739T1/el unknown
-
2021
- 2021-02-17 JP JP2021023741A patent/JP7315598B2/ja active Active
-
2022
- 2022-08-31 US US17/823,905 patent/US20230037373A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10336833B2 (en) | Conjugated anti-CD38 antibodies | |
US9228023B2 (en) | Anti-ROR1 antibodies and methods of use for treatment of cancer | |
US20210371541A1 (en) | Conjugated antiboides against ly75 for the treatment of cancer |